World Neurosurgery
Volume 73, Issue 1 , Pages 22-41 , January 2010

Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage

Received 27 September 2008 ,Accepted 27 May 2009.

References 

  1. Agarwal N, Gordeuk RV, Prchal JT. Genetic mechanisms underlying regulation of hemoglobin mass. Adv Exp Med Biol. 2007;618:195–210
  2. Agil A, Fuller CJ, Jialal I. Susceptibility of plasma to ferrous iron/hydrogen peroxide-mediated oxidation: demonstration of a possible Fenton reaction. Clin Chem. 1995;41:220–225
  3. Aihara Y, Kasuya H, Onda H, et al. Quantitative analysis of gene expressions related to inflammation in canine spastic artery after subarachnoid hemorrhage. Stroke. 2001;32:212–217
  4. Anderson DC, Springer TA. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med. 1987;38:175–194
  5. Ascenzi P, Bocedi A, Visca P, et al. Hemoglobin and heme scavenging. IUBMB Life. 2005;57:749–759
  6. Ascer E, Bertolami MC, Venturinelli ML, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis. 2004;177:161–166
  7. Asleh R, Guetta J, Kalet-Litman S, et al. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96:435–441
  8. Atkinson SH, Mwangi TW, Uyoga SM, et al. The haptoglobin 2-2 genotype is associated with a reduced incidence of Plasmodium falciparum malaria in children on the coast of Kenya. Clin Infect Dis. 2007;44:802–809
  9. Bavbek M, Polin R, Kwan AL, et al. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke. 1998;29:1930–1935[discussion 1935-1936]
  10. Bejjani GK, Duong DH, Kalamarides M, et al. Cerebral vasospasm after tumor resection. A case report. Neurochirurgie. 1997;43:164–168
  11. Blum S, Asaf R, Guetta J, et al. Haptoglobin genotype determines myocardial infarct size in diabetic mice. J Am Coll Cardiol. 2007;49:82–87
  12. Borsody M, Burke A, Coplin W, et al. Haptoglobin and the development of cerebral artery vasospasm after subarachnoid hemorrhage. Neurology. 2006;66:634–640
  13. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 1982;12:189-261, 453-184.
  14. Bowman G, Bonneau RH, Chinchilli VM, et al. A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm. Neurocrit Care. 2006;5:222–229
  15. Bowman G, Dixit S, Bonneau RH, et al. Neutralizing antibody against interleukin-6 attenuates posthemorrhagic vasospasm in the rat femoral artery model. Neurosurgery. 2004;54:719–725[discussion 725-716]
  16. Bruder N, Cohen B, Pellissier D, et al. The effect of hemodilution on cerebral blood flow velocity in anesthetized patients. Anesth Analg. 1998;86:320–324
  17. Campbell JJ, Qin S, Bacon KB, et al. Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. J Cell Biol. 1996;134:255–266
  18. Chaichana K, Riley LH, Tamargo RJ. Delayed cerebral vasospasm secondary to bacterial meningitis after lumbosacral spinal surgery: case report. Neurosurgery. 2007;60:E206–E207discussion E207
  19. Chaichana KL, Levy AP, Miller-Lotan R, et al. Haptoglobin 2-2 genotype determines chronic vasospasm after experimental subarachnoid hemorrhage. Stroke. 2007;38:3266–3271
  20. Chan JR, Hyduk SJ, Cybulsky MI. Chemoattractants induce a rapid and transient up-regulation of monocyte alpha4 integrin affinity for vascular cell adhesion molecule 1 which mediates arrest: an early step in the process of emigration. J Exp Med. 2001;193:1149–1158
  21. Chapelle JP, Albert A, Smeets JP, et al. Effect of the haptoglobin phenotype on the size of a myocardial infarct. N Engl J Med. 1982;307:457–463
  22. Chello M, Carassiti M, Agro F, et al. Simvastatin blunts the increase of circulating adhesion molecules after coronary artery bypass surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2004;18:605–609
  23. Cheong JH, Kim JM, Bak KH, et al. Correlation between cerebral vasospasm after subarachnoid hemorrhage and intracellular adhesion molecule-1 levels in serum and cerebrospinal fluid. J Korean Med Sci. 2005;38:1–11
  24. Chyatte D. Prevention of chronic cerebral vasospasm in dogs with ibuprofen and high-dose methylprednisolone. Stroke. 1989;20:1021–1026
  25. Chyatte D, Fode NC, Nichols DA, et al. Preliminary report: effects of high dose methylprednisolone on delayed cerebral ischemia in patients at high risk for vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1987;21:157–160
  26. Chyatte D, Rusch N, Sundt TM. Prevention of chronic experimental cerebral vasospasm with ibuprofen and high-dose methylprednisolone. J Neurosurg. 1983;59:925–932
  27. Chyatte D, Sundt TM. Response of chronic experimental cerebral vasospasm to methylprednisolone and dexamethasone. J Neurosurg. 1984;60:923–926
  28. Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke. 2001;32:2012–2020
  29. Clatterbuck RE, Gailloud P, Ogata L, et al. Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg. 2003;99:376–382
  30. Clatterbuck RE, Oshiro EM, Hoffman PA, et al. Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats. J Neurosurg. 2002;97:676–682
  31. Clozel M, Breu V, Burri K, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759–761
  32. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498–1505
  33. Cosentino F, McMahon EG, Carter JS, et al. Effect of endothelinA-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm. J Cardiovasc Pharmacol. 1993;22(Suppl 8):S332–S335
  34. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes. 2008;57:1702–1706
  35. Crompton MR. The pathogenesis of cerebral infarction following the rupture of cerebral berry aneurysms. Brain. 1964;87:491–510
  36. Cuzzocrea S. Shock, inflammation and PARP. Pharmacol Res. 2005;52:72–82
  37. Dahlqvist SR, Frohlander N. Haptoglobin groups and rheumatoid arthritis. Hum Hered. 1985;35:207–211
  38. Datta PK, Rappaport J. HIV and complement: hijacking an immune defense. Biomed Pharmacother. 2006;60:561–568
  39. de Fougerolles AR, Stacker SA, Schwarting R, et al. Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J Exp Med. 1991;174:253–267
  40. Diamond MS, Staunton DE, Marlin SD, et al. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell. 1991;65:961–971
  41. Dietrich HH, Dacey RG. Molecular keys to the problems of cerebral vasospasm. Neurosurgery. 2000;46:517–530
  42. Doering TJ, Brix J, Schneider B, et al. Cerebral hemodynamics and cerebral metabolism during cold and warm stress. Am J Phys Med Rehabil. 1996;75:408–415
  43. Doo YC, Han SJ, Han SW, et al. Effect of preexisting statin use on expression of C-reactive protein, adhesion molecules, interleukin-6, and antioxidized low-density lipoprotein antibody in patients with unstable angina undergoing coronary stenting. Clin Cardiol. 2005;28:72–76
  44. Dorsch NW. Cerebral arterial spasm—a clinical review. Br J Neurosurg. 1995;9:403–412
  45. Dulkerian SJ, Kilpatrick L, Costarino AT, et al. Cytokine elevations in infants with bacterial and aseptic meningitis. J Pediatr. 1995;126:872–876
  46. Ecker A, Riemenschneider PA. Arteriographic demonstration of spasm of the intracranial arteries, with special reference to saccular arterial aneurysms. J Neurosurg. 1951;8:660–667
  47. Edwards DH, Byrne JV, Griffith TM. The effect of chronic subarachnoid hemorrhage on basal endothelium-derived relaxing factor activity in intrathecal cerebral arteries. J Neurosurg. 1992;76:830–837
  48. Edwards DH, Griffith TM, Ryley HC, et al. Haptoglobin-haemoglobin complex in human plasma inhibits endothelium dependent relaxation: evidence that endothelium derived relaxing factor acts as a local autocoid. Cardiovasc Res. 1986;20:549–556
  49. Egemen N, Turker RK, Sanlidilek U, et al. The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. Neurol Res. 1993;15:310–315
  50. Egge A, Waterloo K, Sjoholm H, et al. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery. 2001;49:593–605[discussion 605-596]
  51. el Hendawy M, Wronski J, Juniewicz H, et al. Cerebral vasospasm detection by TCD after supratentorial brain tumours surgery. Neurol Neurochir Pol. 2000;34:114–123
  52. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci. 2004;1024:138–146
  53. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569–1582
  54. Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. J Am Soc Echocardiogr. 2007;20:462–469
  55. Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry. 2001;70:534–537
  56. Fassbender K, Ries S, Schminke U, et al. Inflammatory cytokines in CSF in bacterial meningitis: association with altered blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry. 1996;61:57–61
  57. Fassbender K, Schminke U, Ries S, et al. Endothelial-derived adhesion molecules in bacterial meningitis: association to cytokine release and intrathecal leukocyte-recruitment. J Neuroimmunol. 1997;
  58. Feigin VL, Rinkel GJ, Algra A, et al. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology. 1998;50:876–883
  59. Ferris EJ, Rudikoff JC, Shapiro JH. Cerebral angiography of bacterial infection. Radiology. 1968;90:727–734
  60. Filer A, Raza K, Salmon M, et al. Targeting stromal cells in chronic inflammation. Discov Med. 2007;7:20–26
  61. Findlay JM, Kassell NF, Weir BK, et al. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery. 1995;37:168–176[discussion 177-168]
  62. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1–9
  63. Fisher CM, Roberson GH, Ojemann RG. Cerebral vasospasm with ruptured saccular aneurysm–—the clinical manifestations. Neurosurgery. 1977;1:245–248
  64. Florey H. Microscopical observations on the circulation of blood in the cerebral cortex. Brain. 1925;48:43–64
  65. Frazier JL, Pradilla G, Wang PP, et al. Inhibition of cerebral vasospasm by intracranial delivery of ibuprofen from a controlled-release polymer in a rabbit model of subarachnoid hemorrhage. J Neurosurg. 2004;101:93–98
  66. Gabikian P, Clatterbuck RE, Eberhart CG, et al. Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: toxicity and efficacy studies in rabbits and rats. Stroke. 2002;33:2681–2686
  67. Gaetani P, Tartara F, Pignatti P, et al. Cisternal CSF levels of cytokines after subarachnoid hemorrhage. Neurol Res. 1998;20:337–342
  68. Gallia GL, Tamargo RJ. Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage. Neurol Res. 2006;28:750–758
  69. German JW, Gross CE, Giclas P, et al. Systemic complement depletion inhibits experimental cerebral vasospasm. Neurosurgery. 1996;39:141–145[discussion 145-146]
  70. Giblett ER. The haptoglobins of human serum. J Forensic Sci. 1963;8:446–452
  71. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone. 2001;3:50–60
  72. Griffith TM, Edwards DH, Lewis MJ, et al. The nature of endothelium-derived vascular relaxant factor. Nature. 1984;308:645–647
  73. Gull WM. Cases of aneurism of the cerebral vessels. Guys Hosp Rep. 1859;5:281–304
  74. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem. 1995;41:1819–1828
  75. Haley EC, Kassell NF, Apperson-Hansen C, et al. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg. 1997;86:467–474
  76. Haley EC, Kassell NF, Torner JC, et al. A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1994;80:788–796
  77. Hamann G, Isenberg E, Strittmatter M, et al. Absence of elevation of big endothelin in subarachnoid hemorrhage. Stroke. 1993;24:383–386
  78. Handa Y, Hayashi M, Takeuchi H, et al. Effect of cyclosporine on the development of cerebral vasospasm in a primate model. Neurosurgery. 1991;28:380–385[discussion 385-386]
  79. Handa Y, Kabuto M, Kobayashi H, et al. The correlation between immunological reaction in the arterial wall and the time course of the development of cerebral vasospasm in a primate model. Neurosurgery. 1991;28:542–549
  80. Handa Y, Kubota T, Kaneko M, et al. Expression of intercellular adhesion molecule 1 (ICAM-1) on the cerebral artery following subarachnoid haemorrhage in rats. Acta Neurochir (Wien). 1995;132:92–97
  81. Hashi K, Takakura K, Sano K, et al. Intravenous hydrocortisone in large doses in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage–results of a multi-center controlled double-blind clinical study. No To Shinkei. 1988;40:373–382
  82. Hendryk S, Jarzab B, Josko J. Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett. 2004;25:141–147
  83. Henker R, Carlson KK. Fever: applying research to bedside practice. AACN Adv Crit Care. 2007;18:76–87
  84. Hijdra A, van Gijn J, Nagelkerke NJ, et al. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 1988;19:1250–1256
  85. Hino A, Tokuyama Y, Kobayashi M, et al. Increased expression of endothelin B receptor mRNA following subarachnoid hemorrhage in monkeys. J Cereb Blood Flow Metab. 1996;16:688–697
  86. Hofbauer R, Frass M, Gmeiner B, et al. Rapid, fluorescence-based assay for microtiter plates to test drug influences on neutrophil transmigration through endothelial cell monolayers. Life Sci. 1999;65:2453–2461
  87. Hoh BL, Ogilvy CS. Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. Neurosurg Clin N Am 2005;16:501-516, vi.
  88. Hooper DC, Steer CJ, Dinarello CA, et al. Haptoglobin and albumin synthesis in isolated rat hepatocytes. Response to potential mediators of the acute-phase reaction. Biochim Biophys Acta. 1981;653:118–129
  89. Hoshi T, Shimizu T, Kito K, et al. Immunological study of late cerebral vasospasm in subarachnoid hemorrhage. Detection of immunoglobulins, C3, and fibrinogen in cerebral arterial walls by immunofluorescence method. Neurol Med Chir (Tokyo). 1984;24:647–654
  90. Huang J, Choudhri TF, Winfree CJ, et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke. 2000;31:3047–3053
  91. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 2006;66:232–245
  92. Hughes JT, Schianchi PM. Cerebral artery spasm. A histological study at necropsy of the blood vessels in cases of subarachnoid hemorrhage. J Neurosurg. 1978;48:515–525
  93. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989;86:2863–2867
  94. Jackson IJ. Aseptic hemogenic meningitis. An experimental study of aseptic meningeal reactions due to blood and its breakdown products. Arch Neurol Psychiatry. 1949;62:572–589
  95. Jaffar Z, Ferrini ME, Buford MC, et al. Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma. J Immunol. 2007;179:6193–6203
  96. Javid J. The effect of haptoglobin polymer size on hemoglobin binding capacity. Vox Sang. 1965;10:320–325
  97. Jost SC, Diringer MN, Zazulia AR, et al. Effect of normal saline bolus on cerebral blood flow in regions with low baseline flow in patients with vasospasm following subarachnoid hemorrhage. J Neurosurg. 2005;103:25–30
  98. Kallen J, Welzenbach K, Ramage P, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol. 1999;292:1–9
  99. Kaminogo M, Yonekura M, Onizuka M, et al. Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 1998;38:704–708[discussion 708-709]
  100. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996;88:3259–3287
  101. Kapiotis S, Sengoelge G, Sperr WR, et al. Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells. Life Sci. 1996;58:2167–2181
  102. Kassell NF, Haley EC, Apperson-Hansen C, et al. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg. 1996;84:221–228
  103. Kassell NF, Helm G, Simmons N, et al. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg. 1992;77:848–852
  104. Kassell NF, Torner JC, Haley EC, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: overall management results. J Neurosurg. 1990;73:18–36
  105. Kassell NF, Torner JC, Jane JA, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: surgical results. J Neurosurg. 1990;73:37–47
  106. Kasuya H, Onda H, Sasahara A, et al. Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery. 2005;56:895–902[discussion 895-902]
  107. Kasuya H, Shimizu T. Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J Neurosurg. 1989;71:741–746
  108. Kaynar MY, Tanriverdi T, Kafadar AM, et al. Detection of soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in both cerebrospinal fluid and serum of patients after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2004;101:1030–1036
  109. Keyrouz SG, Diringer MN. Clinical review: prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11:220
  110. Kino K, Mizumoto K, Watanabe J, et al. Immunohistochemical studies on hemoglobin-haptoglobin and hemoglobin catabolism sites. J Histochem Cytochem. 1987;35:381–386
  111. Kino K, Tsunoo H, Higa Y, et al. Hemoglobin-haptoglobin receptor in rat liver plasma membrane. J Biol Chem. 1980;255:9616–9620
  112. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987;40:1249–1255
  113. Kinouchi H, Ogasawara K, Shimizu H, et al. Prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage by intraoperative cisternal fibrinolysis using tissue-type plasminogen activator combined with continuous cisternal drainage. Neurol Med Chir (Tokyo). 2004;44:569–575[discussion 576-567]
  114. Klimo P, Kestle JR, MacDonald JD, et al. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004;100:215–224
  115. Koh KK, Son JW, Ahn JY, et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol. 2004;95:185–191
  116. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497
  117. Kohler W, Prokop O. Relationship between haptoglobin and Streptococcus pyogenes T4 antigens. Nature. 1978;271:373
  118. Kordestani RK, Counelis GJ, McBride DQ, et al. Cerebral arterial spasm after penetrating craniocerebral gunshot wounds: transcranial Doppler and cerebral blood flow findings. Neurosurgery. 1997;41:351–359[discussion 359-360]
  119. Kramer AH, Gurka MJ, Nathan B, et al. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage. Neurosurgery. 2008;62:422–427[discussion 427-430]
  120. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198–201
  121. Lange V. Haptoglobin polymorphism—not only a genetic marker. Anthropol Anz. 1992;50:281–302
  122. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589–1600
  123. Larson RS, Springer TA. Structure and function of leukocyte integrins. Immunol Rev. 1990;114:181–217
  124. Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science. 1992;258:964–969
  125. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859–873
  126. Lemanske RF, Busse WW. Asthma. JAMA. 1997;278:1855–1873
  127. Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31:383–391
  128. Levy AP. Genetics of diabetic cardiovascular disease: identification of a major susceptibility gene. Acta Diabetol. 2003;40(Suppl 2):S330–S333
  129. Levy AP, Levy JE, Kalet-Litman S, et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2007;27:134–140
  130. Ley K, Gaehtgens P, Fennie C, et al. Lectin-like cell adhesion molecule 1 mediates leukocyte rolling in mesenteric venules in vivo. Blood. 1991;77:2553–2555
  131. Lin CL, Dumont AS, Calisaneller T, et al. Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm. Surg Neurol. 2005;64:201–205[discussion 205-206]
  132. Lollo BA, Chan KW, Hanson EM, et al. Direct evidence for two affinity states for lymphocyte function-associated antigen 1 on activated T cells. J Biol Chem. 1993;268:21693–21700
  133. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke. 2005;36:2024–2026
  134. Mack WJ, Ducruet AF, Hickman ZL, et al. Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2007;61:255–260[discussion 260-251]
  135. Mack WJ, Mocco J, Hoh DJ, Huang J, Choudhri TF, Kreiter KT, et al. Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;96:71–75
  136. Maiuri F, Gallicchio B, Donati P, et al. The blood leukocyte count and its prognostic significance in subarachnoid hemorrhage. J Neurosurg Sci. 1987;31:45–48
  137. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov. 2003;2:554–565
  138. Manno EM, Gress DR, Ogilvy CS, et al. The safety and efficacy of cyclosporine A in the prevention of vasospasm in patients with Fisher grade 3 subarachnoid hemorrhages: a pilot study. Neurosurgery. 1997;40:289–293
  139. Martin NA, Doberstein C, Alexander M, et al. Posttraumatic cerebral arterial spasm. J Neurotrauma. 1995;12:897–901
  140. Martin NA, Doberstein C, Zane C, et al. Posttraumatic cerebral arterial spasm: transcranial Doppler ultrasound, cerebral blood flow, and angiographic findings. J Neurosurg. 1992;77:575–583
  141. Mascia L, Fedorko L, Stewart DJ, et al. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2001;32:1185–1190
  142. Matsumura Y, Ikegawa R, Suzuki Y, et al. Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: the relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci. 1991;49:841–848
  143. McCormick DJ, Atassi MZ. Hemoglobin binding with haptoglobin: delineation of the haptoglobin binding site on the alpha-chain of human hemoglobin. J Protein Chem. 1990;9:735–742
  144. McGirt MJ, Lynch JR, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke. 2002;33:2950–2956
  145. McGirt MJ, Mavropoulos JC, McGirt LY, et al. Leukocytosis as an independent risk factor for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;98:1222–1226
  146. Melamed-Frank M, Lache O, Enav BI, et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98:3693–3698
  147. Mocco J, Mack WJ, Kim GH, et al. Rise in serum soluble intercellular adhesion molecule-1 levels with vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;97:537–541
  148. Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med. 2004;36:347–354
  149. Mori T, Nagata K, Ishida T, et al. Sequential morphological changes of the constrictive basilar artery in a canine model of experimental cerebral vasospasm by talc injection. J Vet Med Sci. 1994;56:535–540
  150. Mori T, Nagata K, Ishida T, et al. FK-506: a new immunosuppressive agent, failed to reduce cerebral vasospasm after experimental subarachnoid hemorrhage. J Vet Med Sci. 1993;55:581–586
  151. Mori T, Nagata K, Matsui T, et al. Superoxide anions in the pathogenesis of talc-induced cerebral vasocontraction. Neuropathol Appl Neurobiol. 1995;21:378–385
  152. Muizelaar JP, Zwienenberg M, Rudisill NA, et al. The prophylactic use of transluminal balloon angioplasty in patients with Fisher grade 3 subarachnoid hemorrhage: a pilot study. J Neurosurg. 1999;91:51–58
  153. Mukai AO, Krebs VL, Bertoli CJ, et al. TNF-alpha and IL-6 in the diagnosis of bacterial and aseptic meningitis in children. Pediatr Neurol. 2006;34:25–29
  154. Nagata K, Sasaki T, Iwama J, et al. Failure of FK-506, a new immunosuppressant, to prevent cerebral vasospasm in a canine two-hemorrhage model. J Neurosurg. 1993;79:710–715
  155. Nagata K, Sasaki T, Mori T, et al. Cisternal talc injection in dog can induce delayed and prolonged arterial constriction resembling cerebral vasospasm morphologically and pharmacologically. Surg Neurol. 1996;45:442–447
  156. Nam DH, Kim JS, Hong SC, et al. Expression of interleukin-1 beta in lipopolysaccharide stimulated monocytes derived from patients with aneurysmal subarachnoid hemorrhage is correlated with cerebral vasospasm. Neurosci Lett. 2001;312:41–44
  157. Neil-Dwyer G, Cruickshank J. The blood leucocyte count and its prognostic significance in subarachnoid haemorrhage. Brain. 1974;97:79–86
  158. Niikawa S, Hara S, Ohe N, et al. Correlation between blood parameters and symptomatic vasospasm in subarachnoid hemorrhage patients. Neurol Med Chir (Tokyo). 1997;37:881–884[discussion 884-885]
  159. Nishizawa S, Chen D, Yokoyama T, et al. Endothelin-1 initiates the development of vasospasm after subarachnoid haemorrhage through protein kinase C activation, but does not contribute to prolonged vasospasm. Acta Neurochir (Wien). 2000;142:1409–1415
  160. Nishizawa S, Laher I. Signaling mechanisms in cerebral vasospasm. Trends Cardiovasc Med. 2005;15:24–34
  161. Nishizawa S, Peterson JW, Shimoyama I, et al. Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage. Neurosurgery. 1993;32:986–991[discussion 991-982]
  162. Nissen JJ, Mantle D, Blackburn A, et al. The selectin superfamily: the role of selectin adhesion molecules in delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage. Acta Neurochir Suppl. 2000;76:55–60
  163. Nissen JJ, Mantle D, Gregson B, et al. Serum concentration of adhesion molecules in patients with delayed ischaemic neurological deficit after aneurysmal subarachnoid haemorrhage: the immunoglobulin and selectin superfamilies. J Neurol Neurosurg Psychiatry. 2001;71:329–333
  164. Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol. 2008;3–18
  165. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28:477–487
  166. Oertel M, Boscardin WJ, Obrist WD, et al. Posttraumatic vasospasm: the epidemiology, severity, and time course of an underestimated phenomenon: a prospective study performed in 299 patients. J Neurosurg. 2005;103:812–824
  167. Oliveira-Filho J, Ezzeddine MA, Segal AZ, et al. Fever in subarachnoid hemorrhage: relationship to vasospasm and outcome. Neurology. 2001;56:1299–1304
  168. Oshiro EM, Hoffman PA, Dietsch GN, et al. Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats. Stroke. 1997;28:2031–2037[discussion 2037-2038]
  169. Ostergaard JR, Kristensen BO, Svehag SE, et al. Immune complexes and complement activation following rupture of intracranial saccular aneurysms. J Neurosurg. 1987;66:891–897
  170. Otterbein LE, Soares MP, Yamashita K, et al. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 2003;24:449–455
  171. Parra A, Kreiter KT, Williams S, et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery. 2005;56:476–484[discussion 476-484]
  172. Pellettieri L, Carlson CA, Lindholm L. Is the vasospasm following subarachnoidal hemorrhage an immunoreactive disease. Experientia. 1981;37:1170–1171
  173. Pellettieri L, Nilsson B, Carlsson CA, et al. Serum immunocomplexes in patients with subarachnoid hemorrhage. Neurosurgery. 1986;19:767–771
  174. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–1812
  175. Peterson JW, Kwun BD, Hackett JD, et al. The role of inflammation in experimental cerebral vasospasm. J Neurosurg. 1990;72:767–774
  176. Peterson JW, Nishizawa S, Hackett JD, et al. Cyclosporine A reduces cerebral vasospasm after subarachnoid hemorrhage in dogs. Stroke. 1990;21:133–137
  177. Pfister HW, Borasio GD, Dirnagl U, et al. Cerebrovascular complications of bacterial meningitis in adults. Neurology. 1992;42:1497–1504
  178. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298:636–642
  179. Pigott R, Dillon LP, Hemingway IH, et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992;187:584–589
  180. Pimstone NR, Tenhunen R, Seitz PT, et al. The enzymatic degradation of hemoglobin to bile pigments by macrophages. J Exp Med. 1971;133:1264–1281
  181. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005;105:23–56
  182. Pluta RM. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Neurol Res. 2006;28:730–737
  183. Pluta RM, Boock RJ, Afshar JK, et al. Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 1997;87:287–293
  184. Pluta RM, Dejam A, Grimes G, et al. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA. 2005;293:1477–1484
  185. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg. 1997;87:746–751
  186. Polin RS, Bavbek M, Shaffrey ME, et al. Detection of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage. J Neurosurg. 1998;89:559–567
  187. Polin RS, Hansen CA, German P, et al. Intra-arterially administered papaverine for the treatment of symptomatic cerebral vasospasm. Neurosurgery. 1998;42:1256–1264[discussion 1264-1257]
  188. Pozzesi N, Gizzi S, Gori F, et al. IL-2 induces and altered CD4/CD8 ratio of splenic T lymphocytes from transgenic mice overexpressing the glucocorticoid-induced protein GILZ. J Chemother. 2007;19:562–569
  189. Pradilla G, Thai QA, Legnani FG, et al. Local delivery of ibuprofen via controlled-release polymers prevents angiographic vasospasm in a monkey model of subarachnoid hemorrhage. Neurosurgery. 2005;57:184–190[discussion 184-190]
  190. Pradilla G, Thai QA, Legnani FG, et al. Delayed intracranial delivery of a nitric oxide donor from a controlled-release polymer prevents experimental cerebral vasospasm in rabbits. Neurosurgery. 2004;55:1393–1399[discussion 1399-1400]
  191. Pradilla G, Wang PP, Legnani FG, et al. Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits. J Neurosurg. 2004;101:88–92
  192. Pritchard DI. Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005;10:688–691
  193. Qureshi AI, Sung GY, Razumovsky AY, et al. Early identification of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. Crit Care Med. 2000;28:984–990
  194. Rantapaa Dahlqvist S, Beckman G, Beckman L. Serum protein markers in systemic lupus erythematosus. Hum Hered. 1988;38:44–47
  195. Recinos PF, Pradilla G, Thai QA, et al. Controlled release of lipopolysaccharide in the subarachnoid space of rabbits induces chronic vasospasm in the absence of blood. Surg Neurol. 2006;66:463–469[discussion 469]
  196. Rezaie-Majd A, Prager GW, Bucek RA, et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003;23:397–403
  197. Ries S, Schminke U, Fassbender K, et al. Cerebrovascular involvement in the acute phase of bacterial meningitis. J Neurol. 1997;244:51–55
  198. Rinkel GJ, Feigin VL, Algra A, et al. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2004;CD000483
  199. Rittig MG, Kaufmann A, Robins A, et al. Smooth and rough lipopolysaccharide phenotypes of Brucella induce different intracellular trafficking and cytokine/chemokine release in human monocytes. J Leukoc Biol. 2003;74:1045–1055
  200. Rittner HL, Brack A. Leukocytes as mediators of pain and analgesia. Curr Rheumatol Rep. 2007;9:503–510
  201. Robertson EG. Cerebral lesions due to intracranial aneurysms. Brain. 1949;72:150–185
  202. Rosen SD. Cell surface lectins in the immune system. Semin Immunol. 1993;5:237–247
  203. Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–1662
  204. Rothoerl RD, Axmann C, Pina AL, et al. Possible role of the C-reactive protein and white blood cell count in the pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2006;18:68–72
  205. Rousseaux P, Scherpereel B, Bernard MH, et al. Fever and cerebral vasospasm in ruptured intracranial aneurysms. Surg Neurol. 1980;14:459–465
  206. Rowe BH, Chahal AM, Spooner CH, et al. Increasing the use of anti-inflammatory agents for acute asthma in the emergency department: experience with an asthma care map. Can Respir J. 2008;15:20–26
  207. Ryba M, Grieb P, Bidzinski J, et al. Cyclosporine A for the prevention of neurological deficit following subarachnoid hemorrhage. Stroke. 1991;22:531
  208. Ryba M, Jarzabek-Chorzelska M, Chorzelski T, et al. Is vascular angiopathy following intracranial aneurysm rupture immunologically mediated. Acta Neurochir (Wien). 1992;117:34–37
  209. Ryba M, Pastuszko M, Dziewiecki C, et al. A strategy for analyzing multiple parameters with application to aneurysmal SAH patients all of them clipped but treated with and without cyclosporine. Acta Neurochir (Wien). 1993;122:194–199
  210. Ryba M, Pastuszko M, Iwanska K, et al. Cyclosporine A prevents neurological deterioration of patients with SAH—a preliminary report. Acta Neurochir (Wien). 1991;112:25–27
  211. Sadrzadeh SM, Graf E, Panter SS, et al. Hemoglobin. A biologic fenton reagent. J Biol Chem. 1984;259:14354–14356
  212. Saeed SA, Ahmad N, Ahmed S. Dual inhibition of cyclooxygenase and lipoxygenase by human haptoglobin: its polymorphism and relation to hemoglobin binding. Biochem Biophys Res Commun. 2007;353:915–920
  213. Sakurai T, Yanagisawa M, Inoue A, et al. cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun. 1991;175:44–47
  214. Sander D, Klingelhofer J. Cerebral vasospasm following post-traumatic subarachnoid hemorrhage evaluated by transcranial Doppler ultrasonography. J Neurol Sci. 1993;119:1–7
  215. Satoh M, Date I, Nakajima M, et al. Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits. Stroke. 2001;32:225–231
  216. Schenkel AR, Mamdouh Z, Muller WA. Locomotion of monocytes on endothelium is a critical step during extravasation. Nat Immunol. 2004;5:393–400
  217. Schoch B, Regel JP, Wichert M, et al. Analysis of intrathecal interleukin-6 as a potential predictive factor for vasospasm in subarachnoid hemorrhage. Neurosurgery. 2007;60:828–836[discussion 828-836]
  218. Seifert V, Loffler BM, Zimmermann M, et al. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg. 1995;82:55–62
  219. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101–137
  220. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–1197
  221. Sethi S, Sharma P, Dikshit M. Nitric oxide- and oxygen-derived free radical generation from control and lipopolysaccharide-treated rat polymorphonuclear leukocyte. Nitric Oxide. 2001;5:482–493
  222. Shimizu T, Kito K, Hoshi T, et al. Immunological study of late cerebral vasospasm in subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 1982;22:613–619
  223. Shinyama H, Uchida T, Kido H, et al. Phosphoramidon inhibits the conversion of intracisternally administered big endothelin-1 to endothelin-1. Biochem Biophys Res Commun. 1991;178:24–30
  224. Shor M, Boaz M, Gavish D, et al. Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus. Am J Cardiol. 2007;100:1767–1770
  225. Shreenivas S, Oparil S. The role of endothelin-1 in human hypertension. Clin Hemorheol Microcirc. 2007;37:157–178
  226. Sills AK, Clatterbuck RE, Thompson RC, et al. Endothelial cell expression of intercellular adhesion molecule 1 in experimental posthemorrhagic vasospasm. Neurosurgery. 1997;41:453–460[discussion 460-451]
  227. Smithies O. Zone electrophoresis in starch gels: group variations in the serum proteins of normal human adults. Biochem J. 1955;61:629–641
  228. Solenski NJ, Haley EC, Kassell NF, et al. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med. 1995;23:1007–1017
  229. Spallone A, Acqui M, Pastore FS, et al. Relationship between leukocytosis and ischemic complications following aneurysmal subarachnoid hemorrhage. Surg Neurol. 1987;27:253–258
  230. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425–434
  231. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301–314
  232. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol. 1995;57:827–872
  233. Suarez JI, Shannon L, Zaidat OO, et al. Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage. J Neurosurg. 2004;100:585–590
  234. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006;354:387–396
  235. Suzuki SC, Takeichi M. Cadherins in neuronal morphogenesis and function. Dev Growth Differ. 2008;
  236. Takemae T, Mizukami M, Kin H, et al. Computed tomography of ruptured intracranial aneurysms in acute stage-relationship between vasospasm and high density on CT scan. (author's transl) No To Shinkei. 1978;30:861–866
  237. Taneda M, Kataoka K, Akai F, et al. Traumatic subarachnoid hemorrhage as a predictable indicator of delayed ischemic symptoms. J Neurosurg. 1996;84:762–768
  238. Thai QA, Oshiro EM, Tamargo RJ. Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers. Stroke. 1999;30:140–147
  239. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke. 2005;36:1627–1632
  240. Tseng MY, Hutchinson PJ, Czosnyka M, et al. Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:1545–1550
  241. Ursino M, Giulioni M, Lodi CA. Relationships among cerebral perfusion pressure, autoregulation, and transcranial Doppler waveform: a modeling study. J Neurosurg. 1998;89:255–266
  242. Vajkoczy P, Horn P, Bauhuf C, et al. Effect of intra-arterial papaverine on regional cerebral blood flow in hemodynamically relevant cerebral vasospasm. Stroke. 2001;32:498–505
  243. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005;103:9–17
  244. van Deuren M, van der Ven-Jongekrijg J, Bartelink AK, et al. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis. 1995;172:433–439
  245. Van Vlierberghe H, Langlois M, Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta. 2004;345:35–42
  246. Walton JN. The prognosis and management of subarachnoid haemorrhage. Can Med Assoc J. 1955;72:165–175
  247. Wang Y, Zhong M, Tan XX, et al. Expression change of interleukin-8 gene in rabbit basilar artery after subarachnoid hemorrhage. Neurosci Bull. 2007;23:151–155
  248. Watanabe M, Sangawa A, Sasaki Y, et al. Distribution of inflammatory cells in adventitia changed with advancing atherosclerosis of human coronary artery. J Atheroscler Thromb. 2007;14:325–331
  249. Weber C, Erl W, Weber KS, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212–1217
  250. Weir B, Disney L, Grace M, et al. Daily trends in white blood cell count and temperature after subarachnoid hemorrhage from aneurysm. Neurosurgery. 1989;25:161–165
  251. Weir B, Grace M, Hansen J, et al. Time course of vasospasm in man. J Neurosurg. 1978;48:173–178
  252. Wejman JC, Hovsepian D, Wall JS, et al. Structure and assembly of haptoglobin polymers by electron microscopy. J Mol Biol. 1984;174:343–368
  253. Wejman JC, Hovsepian D, Wall JS, et al. Structure of haptoglobin and the haptoglobin-hemoglobin complex by electron microscopy. J Mol Biol. 1984;174:319–341
  254. Weyerbrock A, Walbridge S, Pluta RM, et al. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. J Neurosurg. 2003;99:728–737
  255. White RP, Robertson JT. Comparison of piroxicam, meclofenamate, ibuprofen, aspirin, and prostacyclin efficacy in a chronic model of cerebral vasospasm. Neurosurgery. 1983;12:40–46
  256. Woodside DG, Vanderslice P. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs. 2008;22:85–100
  257. Yamashima T, Kashihara K, Ikeda K, et al. Three phases of cerebral arteriopathy in meningitis: vasospasm and vasodilatation followed by organic stenosis. Neurosurgery. 1985;16:546–553
  258. Yamashima T, Kida S, Yamamoto S. An electron microscopic study of cerebral vasospasm with resultant myonecrosis in cases of subarachnoid haemorrhage, meningitis and trans-sylvian surgery. J Neurol. 1986;233:348–357
  259. Yamaura I, Tani E, Maeda Y, et al. Endothelin-1 of canine basilar artery in vasospasm. J Neurosurg. 1992;76:99–105
  260. Yanamoto H, Kikuchi H, Okamoto S, et al. Cerebral vasospasm caused by cisternal injection of polystyrene latex beads in rabbits is inhibited by a serine protease inhibitor. Surg Neurol. 1994;42:374–381
  261. Yanamoto H, Kikuchi H, Okamoto S, et al. Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits. Neurosurgery. 1992;30:351–356[discussion 356-357]
  262. Yanamoto H, Kikuchi H, Sato M, et al. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery. 1992;30:358–363
  263. Yatsushige H, Yamaguchi M, Zhou C, et al. Role of c-Jun N-terminal kinase in cerebral vasospasm after experimental subarachnoid hemorrhage. Stroke. 2005;36:1538–1543
  264. Zhou C, Yamaguchi M, Kusaka G, et al. Caspase inhibitors prevent endothelial apoptosis and cerebral vasospasm in dog model of experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2004;24:419–431
  265. Zubkov AY, Lewis AI, Raila FA, et al. Risk factors for the development of post-traumatic cerebral vasospasm. Surg Neurol. 2000;53:126–130
  266. Zubkov AY, Rollins KS, Parent AD, et al. Mechanism of endothelin-1-induced contraction in rabbit basilar artery. Stroke. 2000;31:526–533
  267. Zuccarello M, Boccaletti R, Romano A, et al. Endothelin B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm. Stroke. 1998;29:1924–1929
  268. Zucker MB. A study of substances in blood serum and platelets which stimulate smooth muscle. Am J Physiol. 1944;142:12–26

PII: S0090-3019(09)00503-5

doi: 10.1016/j.surneu.2009.05.027

World Neurosurgery
Volume 73, Issue 1 , Pages 22-41 , January 2010

Article Tools

* Image Usage & Resolution